Low pretransplant bone-mineral density and rapid bone loss do not increase risk for avascular osteonecrosis after allogeneic hematopoietic stem cell transplantation

被引:11
|
作者
Schulte, CMS [1 ]
Beelen, DW [1 ]
机构
[1] Univ Hosp Essen, Dept Bone Marrow Transplant, D-45122 Essen, Germany
关键词
avascular osteonecrosis; bone-mineral density; bone loss; risk-factor analysis; stem cell transplantation;
D O I
10.1097/01.TP.0000164353.86447.DB
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Avascular osteonecrosis (AVN) is a serious complication of allogeneic stem cell transplantation (SCT). Graft-versus-host disease and its treatment with steroids are the main risk factors; underlying diagnosis, age and gender are further risk factors. It has been speculated that low baseline bone mineral density (BMD) is associated with AVN posttransplant. Furthermore, rapid bone loss with consecutive microarchitectural changes might prone patients to AVN. Methods. In a single-center prospective cohort study, 255 patients undergoing allogeneic SCT for CML, AML, MDS, and ALL were followed for at least 5 years. We measured BMD (spine, femoral neck, total body) and body indices (body weight, body mass index, body composition determined by dual-energy x-ray absorptiometry) at baseline. Annual changes of BMD and body indices were prospectively observed for 5 years. Incidence of hip AVN necessitating total arthroplasty (severe adverse event) was determined. Univariate and multifactorial nominal logistic as well as Cox proportional hazard analysis were performed. Results. Severe adverse events occurred in nine patients (5-year cumulative incidence rate 6.9%). Baseline BMD and body indices were within normal limits. Rapid and intense bone loss occured, especially during the first year, accompanied by loss of body and especially muscle mass. AVN occurrence was not associated with BMD or body indices at baseline neither with prospectively observed changes of BMD or body indices. Conclusions. AVN is a devastating frequent complication of allogeneous SCT. Allogeneous SCT is followed by dramatic changes in BMD and body composition. However, low BMD and rapid bone loss per se do not dispose patients to AVN occurrence.
引用
收藏
页码:1748 / 1755
页数:8
相关论文
共 50 条
  • [21] Common Genetic Variants Are Associated with Accelerated Bone Mineral Density Loss after Hematopoietic Cell Transplantation
    Yao, Song
    Sucheston, Lara E.
    Smiley, Shannon L.
    Davis, Warren
    Conroy, Jeffrey M.
    Nowak, Norma J.
    Ambrosone, Christine B.
    McCarthy, Philip L., Jr.
    Hahn, Theresa
    PLOS ONE, 2011, 6 (10):
  • [22] Changes in bone mineral density after allogenic stem cell transplantation
    Leguy, Diane
    Magro, Leonardo
    Pierache, Adeline
    Coiteux, Valerie
    Agha, Ibrahim Yakoub
    Cortet, Bernard
    Legroux-Gerot, Isabelle
    JOINT BONE SPINE, 2022, 89 (05)
  • [23] BONE MINERAL DENSITY CHANGES AFTER ALLOGENIC STEM CELL TRANSPLANTATION
    Leguy, D.
    Magro, L.
    Pierache, A.
    Coiteux, V.
    Agha, I. Yakoub
    Cortet, B.
    Legroux-Gerot, I.
    OSTEOPOROSIS INTERNATIONAL, 2020, 31 (SUPPL 1) : S502 - S502
  • [24] Corticosteroid Dose as a Risk Factor for Avascular Necrosis of the Bone after Hematopoietic Cell Transplantation
    McAvoy, Sarah
    Baker, K. Scott
    Mulrooney, Daniel
    Blaes, Anne
    Arora, Mukta
    Burns, Linda J.
    Majhail, Navneet S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (09) : 1231 - 1236
  • [25] Decreased bone mineral density after autologous stem cell transplantation
    Ria, R
    Scarponi, AM
    Falzetti, F
    Ballanti, S
    Di Ianni, M
    Cimminiello, M
    Gasbarrino, C
    Pallone, B
    Russo, F
    Cirulli, T
    Vacca, A
    Dammacco, F
    Mannarino, E
    Martelli, MF
    Tabilio, A
    BLOOD, 2003, 102 (11) : 981A - 981A
  • [26] Low bone mineral density in adolescents with leukemia after hematopoietic stem cell transplantation: prolonged steroid therapy for GvHD and endocrinopathy after hematopoietic stem cell transplantation might be major concerns?
    W K Cho
    M B Ahn
    J-W Lee
    N-G Chung
    M H Jung
    B Cho
    B-K Suh
    Bone Marrow Transplantation, 2017, 52 : 144 - 146
  • [27] Low bone mineral density in adolescents with leukemia after hematopoietic stem cell transplantation: prolonged steroid therapy for GvHD and endocrinopathy after hematopoietic stem cell transplantation might be major concerns?
    Cho, W. K.
    Ahn, M. B.
    Lee, J-W
    Chung, N-G
    Jung, M. H.
    Cho, B.
    Suh, B-K
    BONE MARROW TRANSPLANTATION, 2017, 52 (01) : 144 - 146
  • [28] Screening and Treatment of Low Bone Mineral Density in Allogeneic Hematopoietic Cell Transplant Patients
    Fuchs, Perry
    Ferraro, Christina
    Zhang, Chao
    Deal, Chad
    Hamilton, Betty
    Keller, Sarah
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 3981 - 3983
  • [29] Bone Mineral Density in Children with Fanconi Anemia after Hematopoietic Cell Transplantation
    Petryk, Anna
    Polgreen, Lynda E.
    Barnum, Jessie L.
    Zhang, Lei
    Hodges, James S.
    Baker, K. Scott
    Wagner, John E.
    Steinberger, Julia
    MacMillan, Margaret L.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (05) : 894 - 899
  • [30] Changes in Serum Dickkopf-1, RANK Ligand, Osteoprotegerin, and Bone Mineral Density after Allogeneic Hematopoietic Stem Cell Transplantation Treatment
    Jang, Eunhee
    Ha, Jeonghoon
    Baek, Ki-Hyun
    Kang, Moo Il
    ENDOCRINOLOGY AND METABOLISM, 2021, 36 (06) : 1211 - 1218